# RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

> **NCT05417230** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 29 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** RC48-ADC
- **DRUG:** Envafolimab

## Key facts

- **NCT ID:** NCT05417230
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08
- **Primary completion:** 2024-08
- **Final completion:** 2025-08
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05417230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05417230, "RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05417230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*